The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Geographical variations in left main coronary artery revascularisation: a pre-specified analysis of the EXCEL trial

DOI: 10.4244/EIJ-D-21-00338

1. Sussex Cardiac Centre, Brighton and Sussex University Hospitals NHS Trust, Brighton, United Kingdom; 2. Division of Clinical and Experimental Medicine, Brighton and Sussex Medical School, Brighton, United Kingdom; 3. Clinical Trials Center, Cardiovascular Research Foundation, New York, NY, USA; 4. Hôpital Privé Jacques Cartier, Ramsay Générale de Santé, Massy, France; 5. Piedmont Heart Institute, Atlanta, GA, USA; 6. NewYork-Presbyterian Hospital/Columbia University Medical Center, New York, NY, USA; 7. Department of Cardiology, National University of Ireland Galway (NUIG), Galway, Ireland; 8. Department of Cardiology, Imperial College London, London, United Kingdom; 9. Thoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands; 10. Department of Surgery, UH Cleveland Medical Center, Cleveland, OH, USA; 11. The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA

Background: The EXCEL trial reported similar five-year rates of the primary composite outcome of death, myocardial infarction (MI), or stroke after percutaneous coronary intervention (PCI) compared with coronary artery bypass grafting (CABG) for treatment of obstructive left main coronary artery disease (LMCAD).

Aims: We sought to determine whether these outcomes remained consistent regardless of geography of enrolment.

Methods: We performed a pre-specified subgroup analysis based on regional enrolment.

Results: Among 1,905 patients randomised to PCI (n=948) or CABG (n=957), 1,075 (56.4%) were recruited at 52 European Union (EU) centres, and 752 (39.5%) were recruited at 67 North American (NA) centres. EU versus NA patients varied according to numerous baseline demographics, anatomy, pharmacotherapy and procedural characteristics. Nonetheless, the relative rates of the primary endpoint after PCI versus CABG were consistent across EU versus NA centres at 30 days and 5 years. However, NA participants had substantially higher late rates of ischaemia-driven revascularisation (IDR) after PCI, driven predominantly by the need for greater target vessel and lesion revascularisation. This culminated in a significant difference in the relative risk of the secondary composite outcome of death, MI, stroke, or IDR at 5 years (pinteraction=0.02).

Conclusions: In the EXCEL trial, the relative risks for the 30-day and five-year primary composite outcome of death, MI or stroke after PCI versus CABG were consistent irrespective of geography. However, five-year rates of IDR after PCI were significantly higher in NA centres, a finding the Heart Team and patients should consider when making treatment decisions. ClinicalTrials.gov identifier: NCT01205776

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
A State of the Art on completeness of revascularisation in acute coronary syndromes; device entrapment in CTO-PCI; microvascular perfusion measures; a mini focus on drug-eluting stents; transcatheter mitral valve implantation in patients with prior transcatheter or surgical aortic valve replacement; atherectomy versus surgery in common femoral artery lesions; and more…